As medicinal cannabis (MC) becomes more established in the medicinal sector due to regulatory and attitudinal changes, there has been a corresponding worldwide increase in...
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG). ...
Pearce IP BioBlast® w/e 06 May 2022
29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with or without bevacizumab) for the treatment of persistent,...
Pearce IP leaders ranked by MIP in 2022
Pearce IP congratulates two of its patent leaders for being recognised by Managing IP (MIP) in its 2022 IP Stars ranking. Two Pearce IP leaders Naomi Pearce and Jacinta...
Prototype demonstrations invalidate competitor’s patent
Rakman International Pty Ltd v Boss Fire & Safety Pty Ltd [2022] FCA 464Date:Court:Judge:29 April 2022Federal Court of AustraliaYates JBackground This judgment deals with...
Psychedelic Medicines Part 1
Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately addressed by existing psychiatric or psychological...
Medicinal Cannabis in Australia | Part 1: Available Products
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal cannabis products are not registered on the Australian Register of...
Pearce IP BioBlast® w/e 29 April 2022
21 Apr 22 | AU | Australia’s TGA granted orphan drug designation to Roche’s glofitamab. The TGA also provided approval for Roche to apply for registration using the provisional...
Pearce IP BioBlast® w/e 22 April 2022
14 Apr 22 | CA | BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free biosimilar adalimumab) in Canada. JAMP Pharma has exclusive...
Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the Federal Court found certain batches of Juno’s generic parecoxib...
Artificial intelligence cannot be a patent inventor
Commissioner of Patents v Thaler [2022] FCAFC 62Date:Court:Judges:13 April 2022Full Court of the Federal Court of AustraliaAllsop CJ, Nicholas, Yates, Moshinsky and Burley...
Pearce IP BioBlast w/e 15 April 2022
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved...
The Full Federal Court overturns AI inventorship in Australia
An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by confirming that artificial intelligence (AI) cannot be named...
Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA from threatening patent infringement proceedings against...
Our 2022 Client Survey Results are in!
Thank you to all our clients who participated in the inaugural 2022 Pearce IP “We Hear You” survey. The responses we received included clients providing over 45% of Pearce IP’s...
Pearce IP BioBlast w/e 8 April 2022
31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising in biosimilars, for an upfront EUR 495 million plus...
Full Court confirms expert evidence out of fingolimod trial
Novartis AG v Pharmacor Pty Ltd [2022] FCAFC 58 Date:Court:Judges:4 April 2022Full Federal Court of AustraliaYates, Beach and Moshinsky JJBackground Primary proceedings...
Patent litigation in Australia just got a little cheaper
The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news for the cost of patent litigation in Australia: it may have...
The recipe for success: CSIRO launches bold new protein roadmap
In the quest for a more sustainable future, not least of all in response to the pressing issues of climate change and global population growth, innovative agri-technology and...
Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed
In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator pharmaceutical companies that prevent generic versions of...
Pearce IP BioBlast w/e 1 April 2022
28 Mar 22 | Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded generic formulations and other health care products) for Rs 171...
Gene Therapy 22/23 Budget Announcement Big News for Australian Patients, and for Novartis
The Australian treasurer, Josh Frydenberg used his budget speech yesterday to make several announcements in relation to new pharmaceuticals to be listed in the Australian...
AU Budget 22-23: Highlights for Health, Pharma/Biopharma, Life Sciences & Agribusiness
In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make should the Coalition remain in power after the next election,...
Pearce IP BioBlast w/e 25 March 2022
19 Mar 22 | US | Amgen and Pfizer settled their pegfilgrastim (Neulasta®) dispute Amgen Inc v Hospira Inc (D. Del., No. 20-201) which has been on foot since February 2020. No...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.